Activated oncogenes are the dominant drivers of malignant progression in human cancer, yet little is known about how the transformation from proto-oncogene to activated oncogene drives the expression of transformed phenotypes. An isogenic model of HER2-mediated transformation of human mammary epithelial cells was used along with HER2-amplified human breast cancers to investigate how HER2 activation alters its properties as a signaling molecule and changes the networks of HER2-regulated genes. Our results show that full oncogenic activation of HER2 is the result of a transition in which activated HER2 acquires dominant signaling properties that qualitatively alters the network of genes regulated by the activated oncogene as compared to the protooncogene. As a result, gene expression programs related to invasion, cell stress, and stemness become regulated by HER2 in a manner not observed in non-transformed cells, even when HER-2 is over expressed. Our results offer novel insights into biological processes that come under the control of HER2 after it acquires full oncogenic potential.
Introduction
HER-2 is one of the most well studied of all human cancer genes. HER-2 is known to be a causal factor in approximately 25% of breast cancers and has a role in development of other cancer types as well (1) (2) (3) . HER-2 has dominant transforming activity in vitro and targeted over expression of HER-2 in transgenic mice causes development of mammary tumors (4) (5) (6) (7) (8) (9) (10) . As a signaling molecule, HER-2 is a type I receptor tyrosine kinase with no natural ligand, but with the ability to interact with other HER family members following binding of their cognate ligands (11) (12) . In addition, there is substantial evidence that HER-2 can form constitutively active homodimers that signal in a ligandindependent manner when the receptor is over expressed in cancer cells (13) (14) . Despite the wealth of knowledge regarding the HER-2 oncogene, many questions remain unanswered regarding the biological basis for the transformed phenotypes induced by HER-2 when it is amplified and over expressed.
Previously, we demonstrated that unlike normal breast epithelial cells, breast cancer cells with amplification and over expression of HER-2 exhibit independence of both insulin-like and EGF-like growth factors for continuous proliferation under serumfree conditions (15) (16) (17) (18) (19) (20) . We then demonstrated that the transition to growth factor independence can be mimicked by over expression of HER-2 in MCF-10A cells, which results in insulin-independence; and by co-expression of HER-2 and HPV-E7, which results in insulin and EGF independent growth. The multiple growth factor independence induced by these cooperating oncogenes is identical to what we observed in HER-2 amplified breast cancer cells (6, (20) (21) . Furthermore, EGF-independent MCF-10HER-Thus, the transition to complete growth factor independence is a hallmark of the full transforming function of the HER-2 oncogene.
In the present studies, we sought to explore how signaling from the HER-2 oncoprotein changes as HER-2 acquires full transforming activity and as cells undergo the transition to complete growth factor independence. We also investigated the downstream consequences of HER-2 signaling in growth factor dependent and growth factor-independent cells in order to connect changes in gene expression with the acquisition of biological properties associated with fully transformed cells. The results of these experiments demonstrate that for EGF-dependent but HER-2 over expressing cells, ligand-mediated EGFR activation is the driver of HER-2 tyrosine phosphorylation, which results in significant alterations in down stream gene expression compared to cells expressing physiological levels of HER-2. More importantly however, in HER-2 over expressing, but fully growth factor-independent cells, HER-2 is the driver of EGFR and HER-3 tyrosine phosphorylation, which results in still further alterations in gene expression that are linked to altered biological properties of transformed cells. These results shed new light on the mechanisms by which the fully activated HER-2 oncogene induces malignant transformation. plated so that they reached 75% confluency after 4 days. At this point cultures were treated with the EGFR kinase inhibitor gefitinib (0.5 μM) or HER-2 kinase inhibitor CP724,714 (1 μM ) and RNA was isolated from parallel plated plates at 0, 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42 , and 45 hours after addition of inhibitor. Media was changed the day after plating and at the start of treatment. Quantity measurement and the high quality of all mRNA samples were assured by analysis with the NanoDrop 1000, Agilent Bioanylizer and the Agilent RNA 6000 Nano Kit (Agilent Technologies, Waldbronn, Germany). Expression levels at each time point for each cell and treatment were determined by microarray analyses using the Illumina human Ref8v2 array. Data were processed for quality control and normalized across compared arrays by quantile normalization. 2500 genes with 1.7 or greater expression fold-change at any time point in the series were included in Ingenuity Pathways Analyses. Cluster analysis of expression profiles was performed with Bayesian analysis using CAGED software. A detailed description of the application of this method and the statistical goodness of fit for each cluster are in the supplemental CAGED report. Canonical pathways analysis identified the pathways from the Ingenuity Pathways Analysis library of canonical pathways that were most significant to the data set. Molecules from the data set that met Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Copyright © 2010 American Association for Cancer Research the 1.7 fold-change cut-off and were associated with a canonical pathway in Ingenuity's Knowledge Base were considered for the analysis. The significance of the association between the data set and the canonical pathway was measured in 2 ways: 1) A ratio of the number of molecules from the dataset that map to the pathway divided by the total number of molecules that map to the canonical pathway. 2) Fisher's exact test was used to calculate a p-value determining the probability that the association between the genes in the dataset and the canonical pathway is explained by chance alone.
Measurement of Reactive Oxygen Species (ROS)
ROS levels were measured in live cells using the Image-iT LIVE Green Reactive Oxygen Species Detection Kit (Molecular Probes Inc., Eugene, OR). Cells were exposed to a fluorescein compound that when oxidized emits green fluorescence that was observed by fluorescence microscopy using a Nikon Eclipse TE2000-U microscope (495/529 Ex/Em).
Also, nuclei were stained with Hoeschst 3342 (350/461 Ex/Em).
Reporter Assays
HIF1α reporter assays were performed in MCF-10A, MCF-10HER2 and MCF-10HER2/E7 cells using Cignal Reporter Assay Kits (SABiosciences, Frederick, MD, USA 
Results
To examine the changes in HER-2 signaling that occur as HER-2 over expressing cells , and 21MT-2 (EGF-dependent). We performed experiments with CP724,714, a HER-2-specific small molecule kinase inhibitor that was recently described in detail (24) . We also used the EGFR-selective kinase inhibitor gefitinib at concentrations that are selective for EGFR. The HER-2 and EGFR expression characteristics of the cell lines used in these experiments, as well as data on the specificity of CP724,714 for HER-2 activity are shown in Supplementary Fig. S1 . These ,714 had no effect on tyrosine phosphorylation of EGFR ( Fig. 1A and Fig. S1C ).
By contrast, tyrosine phosphorylation of EGFR was completely inhibited by CP724,714
in the EGF-independent MCF-10HER2/E7 and SUM-225 cells (Fig. 1A) . In addition, We then examined the influence of HER-2 or EGFR kinase activity on the expression and tyrosine phosphorylation of HER-3. Fig. 3A shows that three EGFindependent breast cancer cell lines express higher levels of HER-3 than the EGFdependent 21MT2 cell line. In addition, whereas tyrosine phosphorylated HER-3 was undetectable in the 21MT2 cells, it was readily detectable in the other three cell lines.
Furthermore, HER-3 tyrosine phosphorylation was inhibited by CP724,714, but not by gefitinib in each of the EGF-independent cell lines, whereas gefitinib had no effect on HER-3 tyrosine phosphorylation in these cells. In the MCF-10 cell line series, overall expression of HER-3 was highest in the MCF-10HER-2 cells compared to the other two cell lines (Fig. 3B ). HER-3 tyrosine phosphorylation was low in MCF-10HER-2 cells 3C ). Thus, in growth factor-independent cells, the HER-2 kinase was responsible for tyrosine phosphorylation of HER-3 as well as EGFR.
We then extended the analysis to downstream signaling molecules in two EGFindependent cell lines, and one EGF-dependent breast cancer cell line. Supplementary For example, the specific down-regulation of ROS-reducing enzymes such as SOD2 and GPX4 that act intracellularly and at the cell membrane suggests that the levels of reactive oxygen species could be relatively high in MCF-10HER2/E7 cells. Furthermore, the upregulation of heat shock proteins suggests that these cells may be protected against the negative effects of oxidation by high levels of reactive oxygen species (ROS) that might otherwise cause death in a normal cell. To test these predictions, we measured ROS levels in our isogenic cell lines. Detection of ROS with a live cell assay demonstrated that ROS levels were nearly undetectable in MCF-10A cells, were increased in MCF-10HER-2 cells, and were highest in MCF-10HER2/E7 cells (Fig. 6 ). We then tested for evidence of increased ROS signaling by examining the function of the transcription factor HIF-1α, which is regulated by ROS in addition to hypoxia in cancer cells. 
